Cantargia AB

CANTA · Nasdaq Stockholm · Healthcare

1.41SEK −3.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −44.9%

Performance

1 month

−21.3%

1 year

−44.9%

3 years, per year

−29.9%

5 years, per year

−39.8%

Largest fall, 3 years

−94.1%

Below the peak now

−97.6%

Volatility, 1 year

75.4%

Return with dividends reinvested.

Key figures

P/E

2.0

P/B

1.3

Dividend yield

0.0%

Return on equity

+63.4%

Net margin

+52.8%

Market value

35 m USD

Quality, value and trend

Where Cantargia stands against every Nordic stock today. 100 is best.

Quality97

Profitability and a sound balance sheet over time. Better than 97% of Nordic stocks.

Value91

The price measured against earnings, assets and cash flow. Better than 91% of Nordic stocks.

Trend6

The price development over the past year. Better than 6% of Nordic stocks.

Combined79

Quality, value and trend together. Better than 79% of Nordic stocks.

About Cantargia

Cantargia AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 22 employees.

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis